Live
FierceBiotechOryon shines out of stealth with $21M to fight Parkinson's diseaseFierceBiotechPfizer, Valneva blame low Lyme cases for phase 3 vaccine fail but still plan approval pushIlluminaCanaccord reiterates Hold on Illumina stock amid Roche competition - Investing.com10x Genomics BlogThese Are the Only 3 Stocks That Cathie Wood Bought Last Week - The Motley FoolEndpoints NewsApogee shares positive mid-stage maintenance data for eczema drug that could challenge Dupixent, EbglyssEndpoints NewsArikayce could become Insmed’s second blockbuster following late-stage win in lung infectionEndpoints NewsSanofi extends $180M to California T cell engager startup KaliEndpoints NewsPfizer's Lyme disease vaccine trial hampered by lack of casesIlluminaNordea Investment Management AB Boosts Stake in Illumina - National TodayBioPharma DiveRisk, readiness and resilienceIlluminaIllumina Inc. stock faces renewed scrutiny amid Grail divestiture delays and biotech sector headwind - AD HOC NEWSAgilentAgilent Technologies Advances Chromatography Innovations for Pharma and Biotech Efficiency in 2026 - AD HOC NEWS
BioWorld Jan 13, 2026

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal

Original
Body unavailable. Use the original source.

Directory

59 All